Sino-Argi Leading Biosciences (603970) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sino-Argi Leading Biosciences stock ¥8.32, price ¥10.00, that is 16.8% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range ¥9.63 – ¥25.13 · fair‑value band ¥5.20 – ¥13.17 · the ¥10.00 price screens above the ¥8.32 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Sino-Argi Leading Biosciences in your weekly email
Every Wednesday you see whether Sino-Argi Leading Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products.
Show moreShow less
It also provides plant protection technology services; and crop health solutions, including technical guidance, application demonstration, and processing and packaging of plant protection products. In addition, the company offers insecticides, fungicides, and herbicides products.
The company was founded in 2009 and is headquartered in Beijing, China. Sino-Agri Leading Biosciences Co.,Ltd is a subsidiary of China National Agricultural Means of Production Group Corporation.
Stock analysis
Sino-Argi Leading Biosciences (603970) currently trades at ¥10.00, while our model-based Fair Value estimate is ¥8.32, 17% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥14.13 per share, and 10 of the 17 models we run sit above the ¥10.00 price.
Bear case: the Asset-Based group reads lowest at ¥4.88, and 7 of the 17 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥5.20 (bear) to ¥13.17 (bull), the price of ¥10.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Sino-Argi Leading Biosciences reported revenue of 11.2B CNY in FY2025 versus 8.8B CNY in FY2021, a compound +6.2%/yr. Reported net income was 173M CNY in FY2025, compounding +0.3%/yr from FY2021.
Key figures
Market cap 2.7B CNY (≈ $403M) Small · P/E ratio 17.5 · P/S ratio 0.24 · EPS (TTM) ¥0.5700 · Dividend yield 3.2% · Net margin 1.4% · Return on equity 9.3% · Return on assets (EBIT) 5.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 31 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at 4% fair-value upside, at −17%, 603970 screens richer than that median.
Fair Value models
Bear¥5.20Fair Value ¥8.32Bull¥13.17
Price ¥10.00 · Downside -16.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.2144 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.4%
Dividend (yield on the price)3.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.4% vs 4.7%, steady
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 3%
Compare Sino-Argi Leading Biosciences with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Agricultural Inputs · 162 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−16.8% · Below median
Profitability
Return on equity (12 months)9.3% · Above median
Return on assets3.5% · Below median
Net margin (12 months)1.4% · Bottom 25%
Operating margin (12 months)2.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−1.0% · Below median
Dividend yield (12 months)3.2% · Above median
Balance sheet
Debt / equity0.06× · Above median
Valuation Multiplesvs Agricultural Inputs median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sino-Argi Leading Biosciences Fair Value". https://www.fairvalue-calculator.com/stock/603970
Frequently asked questions
Is Sino-Argi Leading Biosciences (603970) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of ¥8.32 versus a price of ¥10.00, about 17% lower (overvalued).
What is the fair value of 603970?
Our model-based fair value for Sino-Argi Leading Biosciences is ¥8.32 (as of Nov 9, 2026), built from audited fundamentals. The current price: ¥10.00.
What is the quality score of 603970?
Sino-Argi Leading Biosciences has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sino-Argi Leading Biosciences (603970)?
Our model-based price target is the fair value of ¥8.32 (as of Nov 9, 2026) from 17 valuation models. Cautious scenario ¥5.20, optimistic scenario ¥13.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Sino-Argi Leading Biosciences stock forecast for 2026?
Our models put fair value at ¥8.32, about 17% lower versus a price of ¥10.00 (overvalued). Cautious scenario ¥5.20, optimistic scenario ¥13.17. The calculation is refreshed regularly with new filings.
What is the revenue of Sino-Argi Leading Biosciences (603970)?
Sino-Argi Leading Biosciences reported trailing-twelve-month revenue of about 11.3B CNY (latest available figure, as of Nov 9, 2026).
Does Sino-Argi Leading Biosciences pay a dividend?
Sino-Argi Leading Biosciences currently shows a dividend yield of 3.20% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Sino-Argi Leading Biosciences (603970) and when is the ex-dividend date?
Sino-Argi Leading Biosciences pays a dividend of ¥0.32 per share a year, a dividend yield of 3.2%. The last ex-dividend date was Jun 12, 2026. The payout ratio is 56.1% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Sino-Argi Leading Biosciences (603970)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sino-Argi Leading Biosciences it is ¥8.32 per share (as of Nov 9, 2026), against a price of ¥10.00. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Sino-Argi Leading Biosciences stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 603970 trades above its calculated fair value: price ¥10.00, fair value ¥8.32, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603970?
No. The price is what the market pays today (¥10.00); the fair value is what the company's own numbers justify (¥8.32). For Sino-Argi Leading Biosciences the two are ¥1.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sino-Argi Leading Biosciences worth?
The market values Sino-Argi Leading Biosciences at about 2.7B CNY (market capitalisation, as of Nov 9, 2026). Per share that is ¥10.00; our models calculate a fair value of ¥8.32 per share.
What do the bullish and bearish scenarios say about 603970?
Our models span a range for Sino-Argi Leading Biosciences: cautious scenario ¥5.20, base ¥8.32, optimistic ¥13.17 per share (as of Nov 9, 2026, price ¥10.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603970?
Sino-Argi Leading Biosciences trades at a price-to-earnings ratio of 17.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥8.32 is built from several models across several years. Other multiples: P/B 1.7, P/S 0.2, EV/EBITDA 9.4.
How solid is the balance sheet of Sino-Argi Leading Biosciences (603970)?
Balance-sheet figures for Sino-Argi Leading Biosciences (as of Nov 9, 2026): return on equity 9.3%, debt of 0.06 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 603970 from its 52-week high?
Sino-Argi Leading Biosciences trades at ¥10.00, about 30% below its 52-week high of ¥14.27 and 4% above the low of ¥9.63 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥8.32 is for.
Which stocks are comparable to Sino-Argi Leading Biosciences?
From the same area (Basic Materials) we also value Nutrien Ltd, Qinghai Salt Lake Industry Co, CF Industries Holdings, Yara International ASA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sino-Argi Leading Biosciences stock attractive at the current price?
The data as of Nov 9, 2026: price ¥10.00, calculated fair value ¥8.32 (−17%), Quality Score 57/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603970 calculated?
We run Sino-Argi Leading Biosciences through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥8.32 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sino-Argi Leading Biosciences itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sino-Argi Leading Biosciences (603970)?
The closing price on Nov 6, 2026 was ¥10.00. Our model-based fair value is ¥8.32, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sino-Argi Leading Biosciences right now?
Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥5.20 to ¥13.17) leaves room in how you read the outcome.
Where does the earnings growth of Sino-Argi Leading Biosciences (603970) come from?
Earnings per share at Sino-Argi Leading Biosciences grew +7.5 % a year from 2013 to 2024. Broken into its drivers: revenue per share +11.8 %, EBIT margin +1.6 %, tax rate +0.6 %, residual (interest, one-offs) −5.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sino-Argi Leading Biosciences
How large is the market capitalisation of Sino-Argi Leading Biosciences (603970)?
The market capitalisation of Sino-Argi Leading Biosciences is 2.7B CNY (≈ $403M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sino-Argi Leading Biosciences (603970)?
The price-to-sales ratio of Sino-Argi Leading Biosciences is 0.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sino-Argi Leading Biosciences (603970)?
Earnings per share at Sino-Argi Leading Biosciences are ¥0.5700 (price ÷ EPS = P/E 17.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sino-Argi Leading Biosciences (603970)?
The dividend yield of Sino-Argi Leading Biosciences is 3.2% (payout 56.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sino-Argi Leading Biosciences (603970)?
The net margin of Sino-Argi Leading Biosciences is 1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sino-Argi Leading Biosciences (603970)?
The return on equity (ROE) of Sino-Argi Leading Biosciences is 9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sino-Argi Leading Biosciences (603970)?
On an EBIT basis the return on assets of Sino-Argi Leading Biosciences is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sino-Argi Leading Biosciences (603970)?
The operating margin of Sino-Argi Leading Biosciences is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sino-Argi Leading Biosciences (603970)?
Revenue at Sino-Argi Leading Biosciences is growing −1.0% versus a year earlier (3y avg −1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sino-Argi Leading Biosciences (603970)?
Earnings per share at Sino-Argi Leading Biosciences are growing −21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sino-Argi Leading Biosciences (603970) generate?
The free cash flow of Sino-Argi Leading Biosciences is −79.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sino-Argi Leading Biosciences (603970) carry?
The net debt of Sino-Argi Leading Biosciences is 308M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sino-Argi Leading Biosciences in the live analysis
One click puts Sino-Argi Leading Biosciences on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026